| | | Page | | |||
| | | | 1 | | | |
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | |
Name | | | Positions and Offices Held with Scholar Rock | | | Director Since | | | Age | |
Jeffrey S. Flier, M.D. | | | Director | | | 2016 | | | 73 | |
Amir Nashat, Sc.D. | | | Director | | | 2012 | | | 48 | |
Akshay Vaishnaw, M.D., Ph.D. | | | Director | | | 2019 | | | 58 | |
Name | | | Positions and Offices Held with Scholar Rock | | | Director Since | | | Age | |
Nagesh Mahanthappa | | | Director | | | 2021 | | | 57 | |
Joshua Reed | | | Director | | | 2021 | | | 49 | |
Name | | | Positions and Offices Held with Scholar Rock | | | Director Since | | | Class and Year in Which Term Will Expire | | | Age | |
Stuart A. Kingsley | | | President, Chief Executive Officer and Director | | | 2020 | | | Class I – 2022 | | | 57 | |
Joshua Reed | | | Director | | | 2021 | | | Class I – 2022 | | | 48 | |
David Hallal | | | Director | | | 2017 | | | Class II – 2021 | | | 54 | |
Kristina Burow | | | Director | | | 2014 | | | Class II – 2021 | | | 47 | |
Michael Gilman, Ph.D. | | | Director | | | 2013 | | | Class II – 2021 | | | 66 | |
Name | | | Positions and Offices Held with Scholar Rock | | | Director Since | | | Class and Year in Which Term Will Expire | | | Age | |
David Hallal | | | Director | | | 2017 | | | Class II — 2023 | | | 55 | |
Kristina Burow | | | Director | | | 2014 | | | Class II — 2023 | | | 48 | |
Michael Gilman, Ph.D. | | | Director | | | 2013 | | | Class II — 2023 | | | 67 | |
Jeffrey S. Flier, M.D. | | | Director | | | 2016 | | | Class III — 2024 | | | 74 | |
Amir Nashat, Sc. D. | | | Director | | | 2012 | | | Class III — 2024 | | | 49 | |
Akshay Vaishnaw, M.D., Ph.D. | | | Director | | | 2019 | | | Class III — 2024 | | | 59 | |
| Board Size: | | | | | | | | | | | | | | | | | | | |
| Total Number of Directors | | | | | 8 | | | | | | | | | | | | | | |
| Gender: | | | Male | | | Female | | | Non-Binary | | | Gender Undisclosed | | ||||||
| Number of directors based on gender identity | | | | | 7 | | | | | | 1 | | | | | | | | |
| Number of directors who identify in any of the categories below: | | | | | | | | | | | | | | | | | | | |
| African American or Black | | | | | 1 | | | | | | | | | | | | | | |
| Alaskan Native or American Indian | | | | | | | | | | | | | | | | | | | |
| Asian | | | | | 3 | | | | | | | | | | | | | | |
| Hispanic or Latinx | | | | | | | | | | | | | | | | | | | |
| Native Hawaiian or Pacific Islander | | | | | | | | | | | | | | | | | | | |
| White | | | | | 3 | | | | | | 1 | | | | | | | | |
| Two or More Races or Ethnicities | | | | | | | | | | | | | | | | | | | |
| LGBTQ+ | | | | | | | | | | | | | | | | | | | |
| Undisclosed | | | | | | | | | | | | | | | | | | | |
Name | | Position Held with Scholar Rock | | Officer Since | | Age | | | Position Held with Scholar Rock | | Officer Since | | Age | | ||||||
Stuart A. Kingsley | | President & Chief Executive Officer | | 2020 | | 57 | | |||||||||||||
Nagesh K. Mahanthappa, Ph.D. | | Interim Chief Executive Officer & President | | 2021 | | 58 | | |||||||||||||
Gregory J. Carven, Ph.D. | | Chief Scientific Officer | | 2021 | | 45 | | | Chief Scientific Officer | | 2021 | | 46 | | ||||||
Yung H. Chyung, M.D. | | Chief Medical Officer | | 2016 | | 45 | | | Chief Medical Officer | | 2016 | | 46 | | ||||||
Junlin Ho | | General Counsel & Corporate Secretary | | 2021 | | 42 | | |||||||||||||
Edward H. Myles | | Chief Financial Officer and Head of Business Operations | | 2020 | | 49 | | |||||||||||||
Junlin Ho, J.D. | | General Counsel & Corporate Secretary | | 2021 | | 43 | | |||||||||||||
Edward H. Myles, M.B.A. | | Chief Operating Officer and Chief Financial Officer | | 2020 | | 50 | | |||||||||||||
Caryn Parlavecchio | | Chief Human Resources Officer | | 2021 | | 50 | |
| | 2020 | | 2019 | | | 2021 | | 2020 | | ||||||||||||||||
Audit fees(1) | | | $ | 619 | | | | $ | 621 | | | | | $ | 825 | | | | $ | 619 | | | ||||
Audit-related fees(2) | | | | 40 | | | | | — | | | | | | — | | | | | 40 | | | ||||
Tax fees(3) | | | | 179 | | | | | 25 | | | | | | 169 | | | | | 179 | | | ||||
All other fees(4) | | | | 1 | | | | | 2 | | | | | | 1 | | | | | 1 | | | ||||
Total fees | | | $ | 839 | | | | $ | 648 | | | | | $ | 995 | | | | $ | 839 | | |
Name | | | Fees Earned or Paid in Cash ($)(1) | | | Stock Awards ($) | | | Option Awards ($)(3) | | | Total ($) | | ||||||||||||
David Hallal | | | | | 166,972 | | | | | | — | | | | | | 148,363(4) | | | | | | 315,335 | | |
Kristina Burow | | | | | 56,472 | | | | | | — | | | | | | 148,363(5) | | | | | | 204,835 | | |
Jeffrey S. Flier, M.D. | | | | | 57,972 | | | | | | — | | | | | | 148,363(6) | | | | | | 206,335 | | |
Michael Gilman, Ph.D. | | | | | 53,583 | | | | | | — | | | | | | 148,363(7) | | | | | | 201,946 | | |
Amir Nashat, Sc.D. | | | | | 46,472(2) | | | | | | — | | | | | | 148,363(8) | | | | | | 194,835 | | |
Joshua Reed | | | | | 43,389 | | | | | | — | | | | | | 746,318(9) | | | | | | 789,707 | | |
Akshay Vaishnaw, M.D., Ph.D. | | | | | 51,528 | | | | | | — | | | | | | 148,363(10) | | | | | | 199,891 | | |
| | 2020 Annual Retainer | | | 2021 Annual Retainer | | ||||||||
Board of Directors: | | | | | | | | | | | | | ||
Nonemployee member | | | $ | 35,000 | | | | | $ | 40,000(1) | | | ||
Additional fee for Non-Executive Chairman of the Board | | | $ | 115,000 | | | | | $ | 115,000 | | | ||
Audit Committee: | | | | | | | | | | | | | ||
Member | | | $ | 7,500 | | | | | $ | 7,500 | | | ||
Additional fee for Chairman | | | $ | 7,500 | | | | | $ | 7,500 | | | ||
Compensation Committee: | | | | | | | | | | | | | ||
Member | | | $ | 5,000 | | | | | $ | 5,000 | | | ||
Additional fee for Chairman | | | $ | 5,000 | | | | | $ | 5,000 | | | ||
Nominating and Corporate Governance Committee: | | | | | | | | | | | | | ||
Member | | | $ | 4,000 | | | | | $ | 4,000 | | | ||
Additional fee for Chairman | | | $ | 4,000 | | | | | $ | 4,000 | | | ||
Science, Innovation and Technology Committee: | | | | | | | | | | | | | ||
Member | | | $ | 7,500 | | | | | $ | 7,500 | | | ||
Additional fee for Chairman | | | $ | 7,500 | | | | | $ | 7,500 | | |
Name and Principal Position | | | Year | | | Salary ($) | | | Stock Awards ($)(1) | | | Option Award ($)(1) | | | Non-Equity Incentive Plan Compensation ($)(2) | | | All Other Compensation ($)(3) | | | Total ($) | | |||||||||||||||||||||
Stuart A. Kingsley President and Chief Executive Officer | | | | | 2020 | | | | | | 238,000(4) | | | | | | — | | | | | | 4,396,154(6) | | | | | | 312,000 | | | | | | 6,692(11) | | | | | | 4,952,846 | | |
Edward H. Myles Chief Financial Officer & Head of Business Operations | | | | | 2020 | | | | | | 193,500(5) | | | | | | — | | | | | | 2,683,211(7) | | | | | | 208,980 | | | | | | 30,664(12) | | | | | | 3,116,355 | | |
Gregory J. Carven Ph.D. Chief Scientific Officer and former Head of Research | | | | | 2020 | | | | | | 380,785 | | | | | | — | | | | | | 1,019,299 | | | | | | 168,000 | | | | | | 2,548 | | | | | | 1,570,631 | | |
Nagesh K. Mahanthappa, Ph.D. Former President and Chief Executive Officer | | | | | |||||||||||||||||||||||||||||||||||||||
| | | 2020 | | | | | | 306,904(8) | | | | | | 40,743(14) | | | | | | 2,936,796(10) | | | | | | — | | | | | | 846,648(13) | | | | | | 4,058,826 | | | ||
| | | 2019 | | | | | | 500,000 | | | | | | — | | | | | | 1,405,443 | | | | | | 250,000 | | | | | | 3,207 | | | | | | 2,158,650 | | |
Name and Principal Position | | | Year | | | Salary ($) | | | Stock Awards ($)(1) | | | Option Award ($)(1) | | | Non-Equity Incentive Plan Compensation ($)(2) | | | All Other Compensation ($)(3) | | | Total ($) | | |||||||||||||||||||||
Nagesh K. Mahanthappa, Ph.D. Interim Chief Executive Officer and President | | | | | 2021 | | | | | | 219,420(4) | | | | | | — | | | | | | 4,739,043(5) | | | | | | 128,765 | | | | | | 8,036(15) | | | | | | 5,095,264 | | |
| | | 2020 | | | | | | 306,904(6) | | | | | | 40,743(7) | | | | | | 2,936,796(8) | | | | | | — | | | | | | 846,648(9) | | | | | | 4,131,091 | | | ||
Edward H. Myles Chief Operating Officer & Chief Financial Officer | | | | | 2021 | | | | | | 444,769 | | | | | | 1,423,160 | | | | | | 3,477,028 | | | | | | 158,331 | | | | | | 12,765(16) | | | | | | 5,516,053 | | |
| | | 2020 | | | | | | 193,500(10) | | | | | | — | | | | | | 2,683,211(11) | | | | | | 208,980 | | | | | | 30,664(18) | | | | | | 3,116,355 | | | ||
Yung H. Chyung M.D., Chief Medical Officer | | | | | 2021 | | | | | | 444,758 | | | | | | 928,148 | | | | | | 2,267,627 | | | | | | 158,331 | | | | | | 10,518(16) | | | | | | 3,809,382 | | |
Stuart A. Kingsley Former President and Chief Executive Officer | | | | | 2021 | | | | | | 318,500(12) | | | | | | 2,475,060 | | | | | | 6,047,006 | | | | | | — | | | | | | 775,401(13) | | | | | | 9,615,967 | | |
| | | 2020 | | | | | | 238,000(17) | | | | | | — | | | | | | 4,396,154(14) | | | | | | 312,000 | | | | | | 6,692 | | | | | | 4,952,846 | | |
| | | | | | | | | Option Awards | | |||||||||||||||||||||
Name and Principal Position | | | Grant Date | | | Number of Securities Underlying Unexercised Options (# Exercisable) | | | Number of Securities Underlying Unexercised Options (# Unexercisable) | | | Option Exercise Price | | | Option Expiration Date | | |||||||||||||||
Stuart A. Kingsley President and Chief Executive Officer | | | | | 05/20/2020(1) | | | | | | 3,950 | | | | | | 16,366 | | | | | $ | 19.68 | | | | | | 05/20/2030 | | |
| | | 07/16/2020(2) | | | | | | — | | | | | | 429,684 | | | | | $ | 13.83 | | | | | | 07/16/2030 | | | ||
Edward H. Myles Chief Financial Officer | | | | | 11/19/2018(3) | | | | | | 10,722 | | | | | | — | | | | | $ | 20.52 | | | | | | 11/19/2028 | | |
| | | 05/21/2019(4) | | | | | | 5,079 | | | | | | — | | | | | $ | 21.21 | | | | | | 05/21/2029 | | | ||
| | | 07/16/2020(5) | | | | | | — | | | | | | 250,000 | | | | | $ | 13.83 | | | | | | 07/16/2030 | | |
| | | | | | | Option Awards | | | | | | | | Option Awards | | Stock Awards | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Name and Principal Position | | Grant Date | | Number of Securities Underlying Unexercised Options (# Exercisable) | | Number of Securities Underlying Unexercised Options (# Unexercisable) | | Option Exercise Price | | Option Expiration Date | | | Grant Date | | Number of Securities Underlying Unexercised Options (# Exercisable) | | Number of Securities Underlying Unexercised Options (# Unexercisable) | | Option Exercise Price | | Expiration Date | | Number of Shares or Units of Stock That Have Not Vested (#) | | Market Value of Shares or Units of Stock that Have Not Vested ($)(1) | | ||||||||||||||||||||||||||||||||||||||||||||||||
Gregory J. Carven, Ph.D. Chief Scientific Officer and former Head of Research | | | | | 02/20/2018(6) | | | | | 27,694 | | | | | 12,589 | | | | $ | 5.77 | | | | | 02/20/2028 | | | |||||||||||||||||||||||||||||||||||||||||||||||
| | | 05/23/2018(7) | | | | | 6,283 | | | | | 3,771 | | | | $ | 14.00 | | | | | 05/23/2028 | | | |||||||||||||||||||||||||||||||||||||||||||||||||
| | | 01/31/2019(8) | | | | | 17,000 | | | | | 17,000 | | | | $ | 15.11 | | | | | 01/31/2029 | | | |||||||||||||||||||||||||||||||||||||||||||||||||
| | | 02/06/2020(9) | | | | | 7,277 | | | | | 31,536 | | | | $ | 13.52 | | | | | 02/06/2030 | | | |||||||||||||||||||||||||||||||||||||||||||||||||
| | | 05/29/2020(10) | | | | | 6,250 | | | | | 43,750 | | | | $ | 18.40 | | | | | 05/29/2030 | | | |||||||||||||||||||||||||||||||||||||||||||||||||
Nagesh K. Mahanthappa, Ph.D. Former President and Chief Executive Officer | | | | | 02/20/2018(6,11) | | | | | — | | | | | 65,679 | | | | $ | 5.77 | | | | | 02/20/2028 | | | |||||||||||||||||||||||||||||||||||||||||||||||
| | | 05/23/2018(7,11) | | | | | — | | | | | 55,236 | | | | $ | 14.00 | | | | | 05/23/2028 | | | |||||||||||||||||||||||||||||||||||||||||||||||||
| | | 01/31/2019(8,11) | | | | | 8,125 | | | | | 65,000 | | | | $ | 15.11 | | | | | 01/31/2029 | | | |||||||||||||||||||||||||||||||||||||||||||||||||
| | | 02/06/2020(9,11) | | | | | — | | | | | 133,250 | | | | $ | 13.52 | | | | | 02/06/2030 | | | |||||||||||||||||||||||||||||||||||||||||||||||||
Nagesh K. Mahanthappa, Ph.D. Interim Chief Executive Officer and President | | | | | 02/20/2018(2) | | | | | 39,407 | | | | | 13,136 | | | | $ | 5.77 | | | | | 02/20/2028 | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||
| | | 05/23/2018(3) | | | | | 27,618 | | | | | 18,412 | | | | $ | 14.00 | | | | | 05/23/2028 | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||
| | | 01/31/2019(4) | | | | | 24,742 | | | | | 32,500 | | | | $ | 15.11 | | | | | 01/31/2029 | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||
| | | 02/06/2020(5) | | | | | 30,750 | | | | | 92,250 | | | | $ | 13.52 | | | | | 02/06/2030 | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||
Edward H. Myles Chief Operating Officer and Chief Financial Officer | | | | | 07/16/2020(6) | | | | | 15,625 | | | | | 171,875 | | | | $ | 13.83 | | | | | 07/16/2030 | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||
| | | 02/01/2021(7) | | | | | 15,093 | | | | | 65,407 | | | | $ | 58.93 | | | | | 02/01/2031 | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||
| | | 02/01/2021(8) | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 24,150 | | | | $ | 599,886 | | | |||||||||||||||||||||||||||||||||||||||
Yung H. Chyung, M.D., Chief Medical Officer | | | | | 02/20/2018(2) | | | | | 39,406 | | | | | 2,628 | | | | $ | 5.77 | | | | | 02/20/2028 | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||
| | | 01/31/2019(4) | | | | | 42,000 | | | | | 14,000 | | | | $ | 15.11 | | | | | 01/31/2029 | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||
| | | 02/06/2020(5) | | | | | 32,812 | | | | | 42,188 | | | | $ | 13.52 | | | | | 02/06/2030 | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||
| | | 02/21/2021(7) | | | | | 9,843 | | | | | 42,657 | | | | $ | 58.93 | | | | | 02/01/2031 | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||
| | | 02/21/2021(8) | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 15,750 | | | | $ | 391,230 | | |
Plan Category | | Number of securities to be issued upon exercise of outstanding options, warrants and rights (a) | | Weighted-average exercise price of outstanding options, warrants and rights (b) | | Number of securities available for future issuance under equity compensation plans (excluding securities reflected in column (a)) (c) | | | Number of securities to be issued upon exercise of outstanding options, warrants and rights (a) | | Weighted-average exercise price of outstanding options, warrants and rights (b) | | Number of securities available for future issuance under equity compensation plans (excluding securities reflected in column (a)) (c) | | ||||||||||||||||||||||||
Equity compensation plans approved by security holders (1) | | | | 3,679,931 | | | | $ | 14.96 | | | | | 2,758,841(2) | | | | | | 4,058,301 | | | | $ | 25.55(2) | | | | | 3,531,464(3) | | | ||||||
Equity compensation plans not approved by security holders | | | | — | | | | $ | — | | | | | — | | | | | | — | | | | | — | | | | | — | | | ||||||
Total | | | | 3,679,931 | | | | $ | 14.96 | | | | | 2,758,841 | | | | | | 4,058,301 | | | | $ | 25.55 | | | | | 3,531,464 | | |
| | Shares beneficially owned | | | Shares beneficially owned | | ||||||||||||||||||||
Name and address of beneficial owner(1) | | Number | | Percentage | | | Number | | Percentage(1) | | ||||||||||||||||
5% Stockholders: | | | | | | | | | | | | | | | | | | | | | | | ||||
ARCH Venture Fund VIII, L.P.(2) | | | | 2,637,617 | | | | | 7.7% | | | | | | 2,637,617 | | | | | 7.5% | | | ||||
Invus Public Equities, L.P.(3) | | | | 2,100,000 | | | | | 6.1% | | | | | | 2,450,000 | | | | | 6.9% | | | ||||
Polaris Venture Management Co. VI, L.L.C.(4) | | | | 2,832,706 | | | | | 8.2% | | | |||||||||||||||
Entities affiliated with Polaris Venture Partners(4) | | | | 2,549,435 | | | | | 7.2% | | | |||||||||||||||
FMR LLC(5) | | | | 5,045,824 | | | | | 14.7% | | | | | | 5,266,219 | | | | | 14.9% | | | ||||
Redmile Group, LLC(6) | | | | 3,412,009 | | | | | 9.9% | | | | | | 3,624,880 | | | | | 9.9% | | | ||||
BB Biotech AG(7) | | | | 2,255,651 | | | | | 6.6% | | | | | | 2,275,125 | | | | | 6.4% | | | ||||
T. Rowe Price Associates, Inc.(8) | | | | 3,996,494 | | | | | 11.6% | | | | | | 5,262,601 | | | | | 14.9% | | | ||||
BlackRock, Inc.(9) | | | | 2,113,913 | | | | | 6.1% | | | | | | 2,288,026 | | | | | 6.5% | | | ||||
Named Executive Officers and Directors: | | | | | | | | | | | | | | | | | | | | | | | ||||
Stuart A. Kingsley(10) | | | | 15,522 | | | | | * | | | | | | — | | | | | — | | | ||||
Greg J. Carven, Ph.D.(11) | | | | 81,621 | | | | | * | | | |||||||||||||||
Yung H. Chyung, M.D.,(11) | | | | 357,653 | | | | | 1.0% | | | |||||||||||||||
Edward H. Myles(12) | | | | 20,832 | | | | | * | | | | | | 79,483 | | | | | * | | | ||||
Nagesh K. Mahanthappa, Ph.D. (13) | | | | 412,001 | | | | | 1.2% | | | | | | 575,681 | | | | | 1.6% | | | ||||
David Hallal(14) | | | | 410,629 | | | | | 1.2% | | | | | | 459,793 | | | | | 1.3% | | | ||||
Kristina Burow(15) | | | | 2,667,526 | | | | | 7.8% | | | | | | 2,688,891 | | | | | 7.6% | | | ||||
Jeffrey S. Flier, M.D.(16) | | | | 43,580 | | | | | * | | | | | | 65,102 | | | | | * | | | ||||
Michael Gilman, Ph.D.(17) | | | | 68,025 | | | | | * | | | | | | 90,047 | | | | | * | | | ||||
Amir Nashat, Sc.D.(18) | | | | 2,862,615 | | | | | 8.3% | | | | | | 2,608,150 | | | | | 7.4% | | | ||||
Joshua Reed(19) | | | | 866 | | | | | * | | | | | | 6,066 | | | | | * | | | ||||
Akshay Vaishnaw, M.D., Ph.D.(20) | | | | 24,312 | | | | | * | | | | | | 51,884 | | | | | * | | | ||||
All executive officers and directors as a group (13 persons) | | | | 6,982,937 | | | | | 20.3% | | | |||||||||||||||
All executive officers and directors as a group (14 persons) | | | | 7,251,190 | | | | | 20.5% | | |